F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. Issue 1 (1st January 2016)

• Record Type: Journal Article
• Authors: Thibault, Benoît; Clement, Emily; Zorza, Grégoire; Meignan, Samuel; Delord, Jean-Pierre; Couderc, Bettina; Bailly, Christian; Narducci, Fabrice; Vandenberghe, Isabelle; Kruczynski, Anna; Guilbaud, Nicolas; Ferré, Pierre; Annereau, Jean-Philippe
• Is Part Of: Cancer letters. Volume 370:Issue 1(2016)
• Page Start: 10
• Page End: 18
• Publication Date: 2016-01-01
• Subjects: Ovarian cancer -- Topoisomerase II inhibitor -- Polyamine transport system; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.09.006
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: F14512 shows a strong cytotoxic and pro-apoptotic activity in ovarian cancer cells. F14512 efficacy is correlated with F17073 incorporation in ovarian cancer cells. F14512 inhibited tumor growth in a cisplatin-resistant A2780R xenograft model. F17073 fluorescent probe is a tool to evaluate the PTS activity in patients. 83% of patients present a high PTS activity in ovarian cancer cells. Abstract: Epithelial ovarian cancer is the fourth cause of death among cancer-bearing women and frequently associated with carboplatin resistance, underlining the need for more efficient and targeted therapies. F14512 is an epipodophylotoxin-core linked to a spermine chain which enters cells via the polyamine transport system (PTS). Here, we investigate this novel concept of vectorization in ovarian cancer. We compared the effects of etoposide and F14512 on a panel of five carboplatin-sensitive or resistant ovarian cancer models. We assessed the incorporation of F17073, a spermine-linked fluorescent probe, in these cells and in 18 clinical samples. We then showed that F14512 exhibits a high anti-proliferative and pro-apoptotic activity, particularly in cells with high levels of F17073 incorporation. Consistently, F14512 significantly inhibited tumor growth compared to etoposide, in a cisplatin-resistant A2780R subcutaneous model, at a dose of 1.25 mg/kg. In addition, ex vivo analysis indicated that 15 out of 18 patients presented a higher F17073 incorporation into tumor cells compared to normal cells. Overall, our data suggest that F14512, a targeted drug with a potent anti-tumor efficacy, constitutes a potential new therapy for highly PTS-positive and platinum-resistant ovarian cancer-bearing patients.